NEURAL
NEURAL
THERAPEUTICS
Neural Therapeutics Inc. is an ethnobotanical drug discovery/development company focused on developing products and conducting research with psychoactive plants, the first being a cactus commonly known as San Pedro (Echinopsis pachanoi) containing mescaline.
Neural Therapeutics Inc. is an ethnobotanical drug discovery/development company focused on developing products and conducting research with psychoactive plants, the first being a cactus commonly known as San Pedro (Echinopsis pachanoi) containing mescaline.
HANF operates 12 physical stores and an e-commerce platform (www.hanf.com) across in the State of Bavaria in the Federal Republic of Germany. HANF offers a wide range of CBD and private label products sourced from over 40 vendors within the European Union.
Ian Campbell, CEO of Neural, stated: “We are thrilled to embark on this exciting collaboration with the HANF team. CWE’s deep expertise in the natural products and holistic treatment space is a perfect complement to Neural’s focus on ethnobotanical drug development, especially in the realm of psychoactive plants. We believe this partnership will accelerate our efforts in developing innovative pharmaceutical and nutraceutical products.”
To find out more please see Neural’s press release on October 3, 2024
We believe that nearly six thousand years of indigenous experience provides an invaluable source of information that unlocks the key to the capabilities of the whole plant extract. We strive to honor native traditions and treat the San Pedro plant as a source of medicine that the nature has provided.
We believe that nearly six thousand years of indigenous experience provides an invaluable source of information that unlocks the key to the capabilities of the whole plant extract. We strive to honor native traditions and treat the San Pedro plant as a source of medicine that the nature has provided.
Neural Therapeutics Inc. aims to find where the historical use in traditional medicine has proven to be effective and capitalize on the opportunities that can be applied in today’s Nutraceutical and Pharmaceutical markets.
Neural Therapeutics Inc. aims to find where the historical use in traditional medicine has proven to be effective and capitalize on the opportunities that can be applied in today’s Nutraceutical and Pharmaceutical markets.
We begin with a common R&D process that branches into two paths developing pharmaceuticals and nutraceuticals with the aim of utilizing the entire plant and creating zero waste.
We begin with a common R&D process that branches into two paths developing pharmaceuticals and nutraceuticals with the aim of utilizing the entire plant and creating zero waste.
Mr. Campbell is an executive leader with an international reputation in the US, Canada, and Czech Republic for his work in the fields of environmental science and pharmacology.
Dr. Davidovich brings over 20 years of international experience in the pharmaceutical and biotech industries, coupled with a profound expertise in neuromanagement, which applies neuroscience principles to business leadership and marketing.
Mr. Durfy is currently a CEO and Director of High Fusion Inc. Over the past 30 years he has honed his executive experience in operations, investment management, and financial and business strategy.
Mr. Campbell is an executive leader with an international reputation in the US, Canada, and Czech Republic for his work in the fields of environmental science and pharmacology.
Mr. Durfy is currently a CEO and Director of High Fusion Inc. Over the past 30 years he has honed his executive experience in operations, investment management, and financial and business strategy.
Dr. Davidovich brings over 20 years of international experience in the pharmaceutical and biotech industries, coupled with a profound expertise in neuromanagement, which applies neuroscience principles to business leadership and marketing.
Ms. Sosa holds a BSc in Biology and a MA in Holistic Health and Counseling Psychology.
Mr. McLelland started his business career as an accountant at Ernst & Young LLP before moving into mid-market investment banking.
Mr. Gonzalez has over 20 years’ experience in audit & assurance in South America, included 5 years of public and private audit practice, financial analysis, and corporate development in Canada.
Ms. Sosa holds a BSc in Biology and a MA in Holistic Health and Counseling Psychology.
Mr. McLelland started his business career as an accountant at Ernst & Young LLP before moving into mid-market investment banking.
Mr. Gonzalez has over 20 years’ experience in audit & assurance in South America, included 5 years of public and private audit practice, financial analysis, and corporate development in Canada.
David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science at the Imperial College London.
Dr. Fu is one of the few Board-certified Nuclear Pharmacists (BCNP) in the State of Nevada and has extensive experience with mycology.
Dr. Mara Bilibajkich received her medical degree from Queen’s University in Kingston, Ontario, where she also completed her medical residency has been a practicing family physician since 1995.
David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science at the Imperial College London.
Dr. Fu is one of the few Board-certified Nuclear Pharmacists (BCNP) in the State of Nevada and has extensive experience with mycology.
Dr. Mara Bilibajkich received her medical degree from Queen’s University in Kingston, Ontario, where she also completed her medical residency has been a practicing family physician since 1995.
Please provide your email to get a download link for our corporate deck.
|
October 3, 2024 / News Releases
June 27, 2024 / News Releases
May 08, 2024 / News Releases
October 3, 2023 / News Releases
October 2, 2023 / News Releases
May 16, 2024 / Media Releases
February 12, 2024 / Media Releases
February 12, 2024 / Media Releases
December 20, 2023 / Media Releases
December 20, 2023 / Media Releases
December 19, 2023 / Media Releases
December 19, 2023 / Media Releases
December 15, 2023 / Media Releases
December 15, 2023 / Media Releases
December 14, 2023 / Media Releases
December 13, 2023 / Media Releases
December 13, 2023 / Media Releases
December 12, 2023 / Media Releases
December 12, 2023 / Media Releases
December 11, 2023 / Media Releases
October 3, 2023 / Media Releases
September 21, 2023 / Media Releases
September 15, 2023 / Media Releases
July 28, 2023 / Media Releases
July 27, 2023 / Media Releases
June 27, 2023 / Media Releases